Sub-nephrotoxic doses of gentamicin predispose animals to developing acute kidney injury and to excrete ganglioside M2 activator protein

Kidney International

Volumn 78, Issue 10, 2010, Pages 1006-1015

  Quiros, Yaremi ^a,b   Ferreira, Laura ^c   Sancho Martínez, Sandra M ^a,b   González Buitrago, José M ^c   López Novoa, José M ^a,b   López Hernández, Francisco J ^a,b,c  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b Section of Nephrology   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

gentamicin; GM2AP; nephrotoxicity; sensitization to acute kidney injury; urinary markers

Indexed keywords

CISPLATIN; CREATININE; GANGLIOSIDE GM2; GENTAMICIN; IOHEXOL; PLACEBO; URANYL NITRATE;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SENSITIVITY; ENZYMURIA; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; KIDNEY INJURY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; THERAPY EFFECT; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING;

EID: 78049460795     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.267     Document Type: Article

References (58)

1. Kellum JA, Levin N, Bouman C et al. Developing a consensus classification system for acute renal failure. Curr Opin Crit Care 2002; 8: 509-514.
2. Bellomo R, Kellum JA, Ronco C. Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria. Intensive Care Med 2007; 33: 409-413.
3. Neild GH. Multi-organ renal failure in the elderly. Int Urol Nephrol 2001; 32: 559-565.
4. Block CA, Schoolwerth AC. The epidemiology and outcome of acute renal failure and the impact on chronic kidney disease. Semin Dial 2006; 19: 450-454.
5. Kellum JA, Hoste EA. Acute kidney injury: epidemiology and assessment. Scand J Clin Lab Invest Suppl 2008; 241: 6-11.
6. Waikar SS, Liu KD, Chertow GM. Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol 2008; 3: 844-861.
7. Binswanger U. Acute renal failure: changing causes? Kidney Blood Press Res 1997; 20: 163.
8. Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand J Clin Lab Invest Suppl 2008; 241: 89-94.
9. Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 2008; 48: 463-493.
10. Mueller PW, Price RG, Finn WF. New approaches for detecting thresholds of human nephrotoxicity using cadmium as an example. Environ Health Perspect 1998; 106: 227-230.
11. Mingeot-Leclerq MP, Tulkens P. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999; 43: 1003-1012.
12. Mart́?nez-Salgado C, López-Hernández FJ, López-Novoa JM. Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol. 2007: 223, 86-98.
13. Kacew S, Bergeron MG. Pathogenic factors in aminoglycoside-induced nephrotoxicity. Toxicol Lett 1990; 51: 241-259.
14. Laurent G, Kishore BK, Tulkens PM. Aminoglycoside-induced renal phospholipidosis and nephrotoxicity. Biochem Pharmacol 1990; 40: 2383-2392.
15. Leehey DJ, Braun BI, Tholl DA et al. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy. J Am Soc Nephrol 1993; 4: 81-90.
16. Nakakuki M, Yamasaki F, Shinkawa T et al. Protective effect of human ulinastatin against gentamicin-induced acute renal failure in rats. Can J Physiol Pharmacol 1996; 74: 104-111.
17. Xie Y, Nishi S, Iguchi S et al. Expression of osteopontin in gentamicin-induced acute tubular necrosis and its recovery process. Kidney Int 2001; 59: 959-974.
18. Baylis C. The mechanism of the decline in glomerular filtration rate in gentamicin-induced acute renal failure in the rat. J Antimicrob Chemother 1980; 6: 381-388.
19. Avasthi PS, Evan AP, Huser JW et al. Effect of gentamicin on glomerular ultrastructure. J Lab Clin Med 1981; 98: 444-454.
20. Schor N, Ichikawa I, Rennke HG et al. Pathophysiology of altered glomerular function in aminoglycoside-treated rats. Kidney Int 1981; 19: 288-296.
21. Coimbra TM, Lachat JJ. Analysis of urinary albumin excretion in gentamicin-treated rats. Nephron 1988; 49: 154-159.
22. De-Barros-e-Silva ML, Varanda WA, Lachat JJ et al. Glomerular permeability to macromolecules in gentamicin-treated rats. Braz J Med Biol Res 1992; 25: 409-417.
23. Klotman PE, Yarger WE. Reduction of renal blood flow and proximal bicarbonate reabsorption in rats by gentamicin. Kidney Int 1983; 24: 638-643.
24. Goto T, Fujigaki Y, Sun DF et al. Plasma protein extravasation and vascular endothelial growth factor expression with endothelial nitric oxide synthase induction in gentamicin-induced acute renal failure in rats. Virchows Arch 2004; 444: 362-374.
25. Secilmis MA, Karatas Y, Yorulmaz O et al. Protective effect of L-arginine intake on the impaired renal vascular responses in the gentamicin-treated rats. Nephron Physiol 2005; 100: 13-20.
26. Hishida A, Nakajima T, Yamada M et al. Roles of hemodynamic and tubular factors in gentamicin-mediated nephropathy. Ren Fail 1994; 16: 109-116.
27. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 2006; 100: S11-S15.
28. Meier EM, Schwarzmann G, Furst W et al. The human GM2 activator protein. A substrate specific cofactor of beta-hexosaminidase A. J Biol Chem 1991; 266: 1879-1887.
29. Mahuran DJ. The GM2 activator protein, its roles as a cofactor in GM2 hydrolysis and as a general glycolipid transport protein. Biochim Biophys Acta 1998; 1393: 1-18.
30. Mundel TM, Heid HW, Mahuran DJ et al. Ganglioside GM2-activator protein and vesicular transport in collecting duct intercalated cells. J Am Soc Nephrol 1999; 10: 435-443.
31. Yanai H, Yoshida H, Tomoro Y et al. The possible contribution of a general glycosphingolipid transporter, GM2 activator protein, to atherosclerosis. J Atheroscler Thromb 2006; 13: 281-285.
32. Rigat B, Wang W, Leung A et al. Two mechanisms for the recapture of extracellular GM2 activator protein: evidence for a major secretory form of the protein. Biochemistry 1997; 36: 8325-8331.
33. Glombitza GJ, Becker E, Wilhelm Kaiser H et al. Biosynthesis, processing, and intracellular transport of GM2 activator protein in human epidermal keratinocytes. J Biol Chem 1997; 272: 5199-5207.
34. Silverblatt FJ, Kuehn C. Autoradiography of gentamicin uptake by the rat proximal tubule cell. Kidney Int 1979; 15: 335-345.
35. Beauchamp D, Gourde P, Bergeron MG. Subcellular distribution of gentamicin in proximal tubule by immunogold labeling. Antimicrob Agents Chemother 1991; 35: 2173-2179.
36. Sandoval R, Leiser J, Molitoris BA. Aminoglycoside antibiotics traffic to the Golgi complex in LLC-PK1 cells. J Am Soc Nephrol 1998; 9: 167-174.
37. Myrdal SE, Johnson KC, Steyger PS. Cytoplasmic and intranuclear binding of gentamicin does not require endocytosis. Hear Res 2005; 204: 156-169.
38. Oshima M, Hashiguchi M, Shindo N et al. Biochemical mechanisms of aminoglycoside cell toxicity. I. The uptake of gentamicin by subcultured skin fibroblasts and the alteration of lysosomal enzyme activities. J Biochem 1986; 100: 1575-1582.
39. Schacht J. Molecular mechanisms of drug-induced hearing loss. Hear Res 1986; 22: 297-304.
40. Kacew S. Cationic amphiphilic drug-induced renal cortical lysosomal phospholipidosis: an in vivo comparative study with gentamicin and chlorphentermine. Toxicol Appl Pharmacol 1987; 91: 469-476.
41. Ramsammy LS, Josepovitz C, Kaloyanides GJ. Gentamicin inhibits agonist stimulation of the phosphatidylinositol cascade in primary cultures of rabbit proximal tubular cells and rat renal cortex. J Pharmacol Exp Ther 1988; 247: 989-996.
42. Giurgea-Marion L, Toubeau G, Laurent G et al. Impairment of lysosome-pynocytic vesicle fusion in rat kidney proximal tubules after treatment with gentamicin at low doses. Toxicol Appl Pharmacol 1986; 86: 271-285.
43. Van Bambeke F, Tulkens PM, Brasseur R et al. Aminoglycoside antibiotics induce aggregation but not fusion of negatively-charged liposomes. Eur J Pharmacol 1995; 289: 231-233.
44. Deen WM, Lazzara MJ, Myers BD. Structural determinants of glomerular permeability. Am J Physiol Renal Physiol 2001; 281: F579-F596.
45. Deen WM, Lazzara MJ. Glomerular filtration of albumin: how small is the sieving coefficient? Kidney Int Suppl 2004; S63: S64.
46. Haraldsson B, Sorensson J. Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier. News Physiol Sci 2004; 19: 7-10.
47. Schmitz C, Hilpert J, Jacobsen C et al. Megalin deficiency offers protection from renal aminoglyoside accumulation. J Biol Chem 2002; 277: 618-622.
48. Christensen EI, Birn H. Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 2001; 280: F562-F573.
49. Valette JP, Nicot G, Charmes JP et al. Low molecular weight proteins as urinary markers of aminoglycoside nephrotoxicity in man. Proc Eur Dial Transplant Assoc 1979; 16: 597-602.
50. Nicot G, Merle L, Valette JP et al. Gentamicin and sisomicin-induced renal tubular damage. Eur J Clin Pharmacol 1982; 23: 161-166.
51. Bernard A, Viau C, Ouled A et al. Effects of gentamicin on the renal uptake of endogenous and exogenous protein in conscious rats. Toxicol Appl Pharmacol 1986; 84: 431-438.
52. Negri AL. Proximal tubule endocytic apparatus as the specific renal uptake mechanism for vitamin D-binding protein/25-(OH)D3 complex. Nephrology (Carlton) 2006; 11: 510-515.
53. Bergeron M, Mayers P, Brown D. Specific effect of maleate on an apical membrane glycoprotein (gp330) in proximal tubule of rat kidneys. Am J Physiol Renal Fluid Electrolyte Physiol 1996; 271: F908-F916.
54. Nagai J, Tanaka H, Nakanishi N et al. Role of megalin in renal handling of aminoglycosides. Am J Physiol Renal Physiol 2001; 281: F337-F344.
55. Cui S, Verroust PJ, Moestrup SK et al. Megalin/gp330 mediates uptake of albumin in renal proximal tubule. Am J Physiol 1996; 271: F900-F907.
56. Nagai J, Katsube T, Murakami T et al. Effect of gentamicin on pharmacokinetics of lysozyme in rats: interaction between megalin substrates in the kidney. J Pharm Pharmacol 2002; 54: 1491-1496.
57. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
58. López-Novoa JM, Santos JC, Villamediana LM et al. Renal catabolism of 125I-glicentin. Am J Physiol 1986; 250: E545-E550.